B.Riley FBR analyst Madhu Kumar maintained a Hold rating on Arbutus Biopharma Corporation (NASDAQ: ABUS) today and set a price target of $11.50. The company’s shares closed on Friday at $9.45.
According to TipRanks.com, Kumar is a 5-star analyst with an average return of 28.2% and a 52.0% success rate. Kumar covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Clementia Pharmaceuticals Inc, and Deciphera Pharmaceuticals Inc.
Currently, the analyst consensus on Arbutus Biopharma Corporation is a Moderate Buy with an average price target of $10.17, which is a 7.6% upside from current levels. In a report released today, Wedbush also maintained a Hold rating on the stock with a $7 price target.
.
See today’s analyst top recommended stocks >>
Based on Arbutus Biopharma Corporation’s latest earnings release for the quarter ending June 30, the company reported a quarterly net profit of $3.09 million. In comparison, last year the company had a GAAP net loss of $18.26 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Arbutus Biopharma Corp. is a biopharmaceutical company, engages in discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B virus infection. The company was founded on October 6, 2005 and is headquartered in Burnaby, Canada.
